- Home
- GH vs OPCH Comparison
GH vs OPCH Comparison
Compare GH & OPCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- OPCH
- Stock Information
- Founded
- GH 2011
- OPCH N/A
- Country
- GH United States
- OPCH United States
- Employees
- GH N/A
- OPCH N/A
- Industry
- GH Medical Specialities
- OPCH Medical/Nursing Services
- Sector
- GH Health Care
- OPCH Health Care
- Exchange
- GH Nasdaq
- OPCH Nasdaq
- Market Cap
- GH 4.9B
- OPCH 5.3B
- IPO Year
- GH 2018
- OPCH N/A
- Fundamental
- Price
- GH $50.00
- OPCH $31.16
- Analyst Decision
- GH Strong Buy
- OPCH Strong Buy
- Analyst Count
- GH 20
- OPCH 7
- Target Price
- GH $54.35
- OPCH $35.86
- AVG Volume (30 Days)
- GH 2.1M
- OPCH 1.7M
- Earning Date
- GH 08-06-2025
- OPCH 07-30-2025
- Dividend Yield
- GH N/A
- OPCH N/A
- EPS Growth
- GH N/A
- OPCH N/A
- EPS
- GH N/A
- OPCH 1.25
- Revenue
- GH $773,996,000.00
- OPCH $5,185,122,000.00
- Revenue This Year
- GH $23.14
- OPCH $13.22
- Revenue Next Year
- GH $21.42
- OPCH $8.52
- P/E Ratio
- GH N/A
- OPCH $24.89
- Revenue Growth
- GH 28.20
- OPCH 16.98
- 52 Week Low
- GH $20.14
- OPCH $21.39
- 52 Week High
- GH $53.42
- OPCH $35.53
- Technical
- Relative Strength Index (RSI)
- GH 60.59
- OPCH 43.52
- Support Level
- GH $48.07
- OPCH $30.79
- Resistance Level
- GH $53.42
- OPCH $32.53
- Average True Range (ATR)
- GH 2.25
- OPCH 0.74
- MACD
- GH -0.12
- OPCH -0.03
- Stochastic Oscillator
- GH 55.56
- OPCH 21.26
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.